Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
NCT01734928Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2013
- Primary completion
- May 2022
- Modality
- Molecular Glues
- Countries
- 22
01
Overview
A Phase 3 trial of pomalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Jan 2013; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01734928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734928.